An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Operating Expenses | 15,880 | 18,296 | 18,815 | 18,180 | 16,601 |
| Operating Income | -15,880 | -18,296 | -18,815 | -18,180 | -16,601 |
| Other Income | 1,445 | 1,679 | 1,917 | 1,473 | 797 |
| Pre-tax Income | -14,435 | -16,617 | -16,898 | -16,707 | -15,804 |
| Net Income Continuous | -14,435 | -16,617 | -16,898 | -16,707 | -15,804 |
| Net Income | $-14,435 | $-16,617 | $-16,898 | $-16,707 | $-15,804 |
| EPS Basic Total Ops | -0.48 | -0.56 | -0.49 | -0.65 | -0.81 |
| EPS Basic Continuous Ops | -0.48 | -0.56 | -0.49 | -0.65 | -0.81 |
| EPS Diluted Total Ops | -0.48 | -0.56 | -0.49 | -0.65 | -0.81 |
| EPS Diluted Continuous Ops | -0.48 | -0.56 | -0.49 | -0.65 | -0.81 |
| EPS Diluted Before Non-Recurring Items | -0.48 | -0.56 | -0.57 | N/A | N/A |
| EBITDA(a) | $-16,770 | $-19,387 | $-20,121 | $-18,833 | $-17,062 |